Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing transformative therapies to treat patients with cancer. Biomea Fusion's lead product candidate, BMF-219, is an oral, selective inhibitor of the fusion of NTRK1, NTRK2, and NTRK3 genes, which is in Phase 1/2 clinical trial for adult patients with solid tumors harboring an NTRK gene fusion. The Company is also developing BMF-119, a selective inhibitor of the fusion of MET exon 14 and other MET alterations. Biomea Fusion, Inc. is based in Brisbane, California.